Source link : https://www.newshealth.biz/health-news/novel-glucagon-glp-1-receptor-dual-agonist-improved-mash-in-phase-ii-study/
Survodutide, a novel glucagon/GLP-1 receptor dual agonist, improved metabolic dysfunction-associated steatohepatitis (MASH) with no worsening of fibrosis, according to results of a phase II trial. Among 293 patients with biopsy-confirmed MASH and F1 to F3 fibrosis, improvement in MASH with no worsening of fibrosis occurred in 47% of the patients in the 2.4-mg survodutide group, […]
Author : News Health
Publish date : 2024-06-07 20:15:51
Copyright for syndicated content belongs to the linked Source.
Categories